Polycythemia Vera – Evidence‑Based Diagnostic and Therapeutic Guidelines

Diagnostic Workup

JAK2 V617F mutation is present in >95 % of polycythemia vera (PV) cases, making it the most definitive molecular test. The American Society of Hematology (ASH) recommends routine testing for this mutation in all patients with sustained erythrocytosis. 1
Low or inappropriately normal serum erythropoietin (EPO) has >90 % specificity for PV, but its sensitivity is only 64‑70 %; a normal EPO level does not exclude the disease. The World Health Organization (WHO) advises using EPO in conjunction with JAK2 testing. 1
Bone‑marrow biopsy showing hypercellularity with pan‑myelosis, increased megakaryocyte clusters, and decreased iron stores confirms PV when molecular or EPO data are equivocal. WHO 2016 criteria incorporate these morphologic features. 1
WHO 2016 diagnostic criteria for PV require either:

Patients are classified as high‑risk if they are >60 years of age or have a prior thrombotic event; all others are low‑risk. This stratification guides the need for cytoreductive therapy. 1

Therapeutic phlebotomy to keep hematocrit <45 % reduces thrombotic complications and improves overall survival. The American Society of Clinical Oncology (ASCO) recommends this target hematocrit threshold. 1
Low‑dose aspirin (≈100 mg daily) significantly lowers the incidence of vascular events without a marked increase in major bleeding. ASCO endorses routine aspirin in PV unless contraindicated. 1
Aggressive control of cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and smoking cessation are mandatory components of management. ASCO emphasizes these measures for all risk categories. 1

Hydroxyurea is the preferred first‑line cytoreductive agent for most high‑risk patients. Dose is titrated to maintain platelet count <400 × 10⁹/L and white‑blood‑cell count <10 × 10⁹/L. 1
Caution is advised when using hydroxyurea in patients <40 years because of a potential leukemogenic risk. ASCO recommends alternative agents in this age group. 1
Interferon‑α (including pegylated formulations) is an alternative first‑line option, especially for younger patients, and can achieve molecular remission with reduction of the JAK2 V617F allele burden. ASCO lists interferon as a viable substitute. 1
Busulfan may be considered for elderly patients (≈>70 years) when other agents are unsuitable. ASCO includes busulfan as a second‑line cytoreductive drug. 1
Additional indications for initiating cytoreductive therapy (regardless of age or thrombosis history) include:

The European LeukemiaNet (ELN) clinico‑hematologic criteria are used to assess response to cytoreductive therapy. ELN recommends regular CBC monitoring rather than routine bone‑marrow biopsies. 1
Routine measurement of JAK2 V617F allele burden is not required, except when interferon‑α is employed, as molecular response may guide therapy. ASCO advises selective allele‑burden testing. 1
Stable patients should have complete blood counts and relevant clinical parameters checked every 3–6 months; newly diagnosed or unstable patients require monthly monitoring for the first three months. These intervals are derived from consensus guidelines. 5

Do not rule out PV on the basis of a normal EPO level alone, because the test’s sensitivity is limited (≈64‑70 %). ASCO cautions against over‑reliance on EPO. 5
Do not dismiss PV when hemoglobin is normal or borderline‑high with microcytosis; iron deficiency can mask the expected hemoglobin rise. In such cases, proceed with JAK2 testing if additional clues (e.g., thrombocytosis, splenomegaly, pruritus) are present. 5
Red cell mass measurement is no longer routinely required, as modern JAK2 and EPO testing provide sufficient diagnostic accuracy. WHO recommends reserving this test for atypical scenarios. 3
Always evaluate smoking as a reversible cause of secondary polycythemia; cessation leads to risk reduction within one year. ASCO includes smoking assessment in the work‑up. 5

Avoid aggressive or repeated phlebotomies in secondary polycythemia, as this can precipitate iron deficiency, reduce oxygen‑carrying capacity, and increase stroke risk. ASCO advises limiting phlebotomy to true PV. 5
Do not use cytoreductive drugs in low‑risk patients who have well‑controlled cardiovascular risk factors; phlebotomy and aspirin are sufficient. ASCO specifies cytoreduction only for high‑risk or symptomatic cases. 1